WHO naming stem · suffix · 28 listed names
-citabine
This page was written with AI.
nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives
Where it sits in a name
WHO writes the stem as -citabine. So the letters citabine sit at the end of the name (…citabine).
All 28 names WHO lists under -citabine
These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.
Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 5 of 28 names appear in these lists: 5 in the US list (FDA Drugs@FDA) and 3 in the EU central list (EMA); 4 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.
- ancitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- apricitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- capecitabineEU (central) brands: Capecitabine Accord, Capecitabine Medac, Capecitabine Teva, Ecansya, Xeloda, Capecitabine SUN (withdrawn)
- decitabineEU (central) brands: Dacogen
- dexelvucitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- elvucitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- emtricitabineUS brands: EMTRIVAin combination: BIKTARVY with bictegravir + tenofovir alafenamide; COMPLERA with rilpivirine + tenofovir disoproxil; DESCOVY with tenofovir alafenamide; GENVOYA with cobicistat + elvitegravir + tenofovir alafenamide; ODEFSEY with rilpivirine + tenofovir alafenamide; STRIBILD with cobicistat + elvitegravir + tenofovir disoproxil; SYMTUZA with cobicistat + darunavir + tenofovir alafenamide; TRUVADA with tenofovir disoproxil; ATRIPLA (discontinued in FDA listings) with efavirenz + tenofovir disoproxilEU (central) brands: Emtrivain combination: Biktarvy with bictegravir + tenofovir alafenamide; Descovy with tenofovir alafenamide; Efavirenz/Emtricitabine/Tenofovir disoproxil Krka with efavirenz + tenofovir disoproxil; Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan with efavirenz + tenofovir disoproxil; Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva with efavirenz + tenofovir disoproxil; Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris with rilpivirine + tenofovir alafenamide; Emtricitabine / Tenofovir alafenamide Viatris with tenofovir alafenamide; Emtricitabine/Tenofovir disoproxil Krka with tenofovir disoproxil; Emtricitabine/Tenofovir disoproxil Krka d.d. with tenofovir disoproxil; Emtricitabine/Tenofovir disoproxil Mylan with tenofovir disoproxil; Emtricitabine/Tenofovir disoproxil Zentiva with tenofovir disoproxil; Eviplera with rilpivirine + tenofovir disoproxil
6 more
Genvoya with cobicistat + elvitegravir + tenofovir alafenamide; Odefsey with rilpivirine + tenofovir alafenamide; Stribild with cobicistat + elvitegravir + tenofovir disoproxil; Symtuza with cobicistat + darunavir + tenofovir alafenamide; Truvada with tenofovir disoproxil; Atripla (withdrawn) with efavirenz + tenofovir disoproxil - enocitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- fiacitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- flurocitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- fosgemcitabine palabenamideNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- fostroxacitabine bralpamideNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- galocitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- gemcitabineUS brands: AVGEMSI, INLEXZO, GEMZAR (discontinued in FDA listings), INFUGEM (discontinued in FDA listings)EU (central) brands: none found
- gemcitabine elaidateNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- guadecitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- ibacitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- lumicitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- mericitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- radgocitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- roducitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- sapacitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- tezacitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- torcitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- troxacitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- valopicitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- valtorcitabineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- zalcitabineEU (central) brands: none found
US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.
EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.
EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.
Same group, without the stem
WHO also lists these 2 names under -citabine: group (c) of Part IV of the 2024 stem book, “INN which belong to the same group of pharmaceutical substances but in which the stem is not used”. They belong to the same group of substances as the group (a) names above, yet they do not carry -citabine, so the name alone does not reveal the group.
- azacitidine
- cytarabine
Decode another name
Decoded
ancitabine
Listed INNCarries 3 WHO stems, most specific first: -citabine …
- -citabineend of the nameWHO lists it hereWHO definition: nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives
- -(ar)abineend of the nameWHO lists it hereWHO definition: arabinofuranosyl derivatives
- -abineend of the nameWHO lists it hereWHO definition: arabinofuranosyl derivatives; nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives
“ancitabine” is an INN that WHO lists under -citabine, -(ar)abine, -abine in the 2024 stem book.
The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.
Source and licence
The definition of -citabine (Part II B) and the 28 names (Part IV, group (a)), and the 2 of the same group without the stem (group (c)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .
Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.